You just read:

Bridge Biotherapeutics Signs US$40M License Agreement with Daewoong Pharmaceutical for Co-development of UC Drug Candidate

News provided by

Bridge Biotherapeutics, Inc.

Dec 18, 2018, 19:00 ET